Literature DB >> 3740921

Minimal change nephrotic syndrome and cyclophosphamide.

R S Trompeter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3740921      PMCID： PMC1777922          DOI： 10.1136/adc.61.8.727

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN： 0003-9888            Impact factor:   3.791


× No keyword cloud information.
  15 in total

1.  EXPERIENCE WITH ALKYLATING AGENTS IN THE TREATMENT OF CHILDREN WITH THE NEPHROTIC SYNDROME.

Authors:  J H COLDBECK
Journal:  Med J Aust       Date:  1963-12-14       Impact factor: 7.738

2.  Comparative trial of 2 weeks and 8 weeks cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood.

Authors:  T M Barratt; J S Cameron; C Chantler; C S Ogg; J F Soothill
Journal:  Arch Dis Child       Date:  1973-04       Impact factor: 3.791

3.  Long-term assessment of cyclophosphamide therapy for nephrosis in children.

Authors:  J McDonald; A V Murphy; G C Arneil
Journal:  Lancet       Date:  1974-10-26       Impact factor: 79.321

4.  Idiopathic nephrotic syndrome of childhood: cyclophosphamide induced conversion from steroid refractory to highly steroid sensitive disease.

Authors:  A Bergstrand; I Bollgren; A Samuelsson; T Törnroth; J Wasserman; J Winberg
Journal:  Clin Nephrol       Date:  1973 Sep-Oct       Impact factor: 0.975

5.  Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood.

Authors:  T M Barratt; J F Soothill
Journal:  Lancet       Date:  1970-09-05       Impact factor: 79.321

6.  A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood.

Authors:  J Chiu; P N McLaine; K N Drummond
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

7.  Therapeutic and toxic effects observed with different dosage programs of cyclophosphamide in treatment of steroid-responsive but frequently relapsing nephrotic syndrome.

Authors:  W W McCrory; M Shibuya; W H Lu; J E Lewy
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

8.  Gonadal effects of chlorambucil given to prepubertal and pubertal boys for nephrotic syndrome.

Authors:  P Guesry; G Lenoir; M Broyer
Journal:  J Pediatr       Date:  1978-02       Impact factor: 4.406

9.  Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood.

Authors:  T M Barratt; A Bercowsky; S G Osofsky; J F Soothill
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

10.  Long-term stability of remission in nephrotic syndrome after treatment with cyclophosphamide.

Authors:  J S Cameron; C Chantler; C S Ogg; R H White
Journal:  Br Med J       Date:  1974-10-05
View more
  8 in total

Review 1.  Treatment of steroid sensitive nephrotic syndrome.

Authors:  A S Abeyagunawardena
Journal:  Indian J Pediatr       Date:  2005-09       Impact factor: 1.967

2.  Minimal change nephrotic syndrome and cyclophosphamide.

Authors:  J S Lilleyman
Journal:  Arch Dis Child       Date:  1987-02       Impact factor: 3.791

Review 3.  Glomerulonephritis: diagnosis and treatment.

Authors:  P D Mason; C D Pusey
Journal:  BMJ       Date:  1994-12-10

4.  Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome.

Authors:  Ahmet Taner Elmas; Yılmaz Tabel; Ozlem Nalbantoğlu Elmas
Journal:  Int Urol Nephrol       Date:  2012-07-24       Impact factor: 2.370

5.  Long-term effects of levamisole treatment in childhood nephrotic syndrome.

Authors:  Viktória Sümegi; Ibolya Haszon; Béla Iványi; Csaba Bereczki; Ferenc Papp; Sándor Túri
Journal:  Pediatr Nephrol       Date:  2004-12       Impact factor: 3.714

6.  The use of steroid-sparing agents in steroid-sensitive nephrotic syndrome.

Authors:  Asiri S Abeyagunawardena; Michael J Dillon; Lesley Rees; William van't Hoff; Richard S Trompeter
Journal:  Pediatr Nephrol       Date:  2003-07-23       Impact factor: 3.714

7.  Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

Authors:  Narayan Prasad; Sanjeev Gulati; Raj Kumar Sharma; Uttam Singh; Muffazal Ahmed
Journal:  Pediatr Nephrol       Date:  2004-03-09       Impact factor: 3.714

8.  Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.

Authors:  Roberta Fenoglio; Savino Sciascia; Giulietta Beltrame; Paola Mesiano; Michela Ferro; Giacomo Quattrocchio; Elisa Menegatti; Dario Roccatello
Journal:  Oncotarget       Date:  2018-06-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.